Wanxing Chai-Ho, MD
Hematology & Oncology · Los Angeles, CANPI 1023371515
Payments from drug & device makers
Across 152 payments — averaging $11,871 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$934K
- Merck$532K
- Incyte Corporation$119K
- Agios Pharmaceuticals, Inc.$69K
- AbbVie$55K
- Bristol Myers Squibb$52K
- plus $44K from 18 others
What the payments were for
- Consulting fees$5,00078%
- Speaking & faculty fees$1502%
- Food & beverage$1,25520%
- Education$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 5 | $934,374 |
| Merck | 12 | $531,623 |
| Incyte Corporation | 52 | $118,936 |
| Agios Pharmaceuticals, Inc. | 7 | $68,616 |
| AbbVie | 8 | $54,835 |
| Bristol Myers Squibb | 2 | $52,349 |
| Sanofi US Services Inc. | 4 | $13,993 |
| E.r. Squibb & Sons, L.L.C. | 5 | $13,254 |
| Macrogenics, Inc. | 4 | $9,494 |
| Daiichi Sankyo Inc. | 32 | $1,840 |
| Organon | 1 | $1,714 |
| Servier Pharmaceuticals LLC | 1 | $1,680 |
| Kadmon Corporation LLC | 1 | $649 |
| AstraZeneca(2 entities) | 2 | $285 |
| Pfizer | 2 | $143 |
| Pharmaessentia USA Corporation | 1 | $133 |
| Blueprint Medicines Corporation | 1 | $132 |
| Johnson & Johnson | 4 | $108 |
| Beigene USA, Inc. | 2 | $64 |
| Jazz Pharmaceuticals Inc. | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| GSK | 1 | $29 |
| Sanofi | 1 | $25 |
| Gilead | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,804,377 in reported general payments places this provider in the 90th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 56 | $706,679 |
| BesremiRopeginterferon Alfa-2b-Njft | 23 | $379,660 |
| MekinistTrametinib Dimethyl Sulfoxide | 14 | $217,414 |
| VenclextaVenetoclax | 43 | $214,511 |
| TafinlarDabrafenib Mesylate | 14 | $169,654 |
| InqoviDecitabine/Cedazuridine | 15 | $122,610 |
| CresembaIsavuconazonium Sulfate | 15 | $86,224 |
| Posaconazole | 44 | $42,114 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 19 | $33,299 |
| EliquisApixaban | 18 | $21,005 |
| Acyclovir | 83 | $1,510 |
| Budesonide DrBudesonide | 12 | $919 |
| ValacyclovirValacyclovir Hcl | 28 | $876 |
| Levofloxacin | 63 | $720 |
| Ondansetron Hcl | 39 | $648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $118,936 | $706,67956 claims |
| NovartisMekinist, Tafinlar | $934,374 | $387,06728 claims |
| Pharmaessentia USA CorporationBesremi | $133 | $379,66023 claims |
| AbbVieVenclexta | $54,835 | $214,51143 claims |
| PfizerEliquis | $143 | $21,00518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Los Angeles
- David BerzLos Angeles$43.3M
- Nicholas McAndrewLos Angeles$22.9M
- Antoni RibasLos Angeles$13M
- Gary SchillerLos Angeles$11.9M
- Matthew RettigLos Angeles$8.2M
- Lasika SeneviratneLos Angeles$8.1M
- Gary BuchschacherLos Angeles$7.9M
- Edward GaronLos Angeles$7.9M
- Gottfried KonecnyLos Angeles$7.6M
- Sven de VosLos Angeles$6.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.